From Bell Potter -
Biomarker Data Remains Highly Supportive
PAR continues to make every post a winner with the latest data from the company’s
phase 2 randomised clinical trial providing further evidence of efficacy and safety for
iPPS. PARA_OA_008 was designed to generate data to test the hypothesis that
changes in the biomarkers correlate with knee pain reduction and improved knee
function. The key data released today concerned the secondary endpoints of
radiographic changes in bone/ joint together with further data on biomarkers.
Imaging showed a material improvement in cartilage degradation for participants on
drug vs control. Both the once weekly and twice weekly dose groups showed trends of
improvement in cartilage preservation compared to control with the once weekly dose
cohort achieving statistical significance despite small participant numbers.
A broad panel of potential biomarkers in blood, urine and synovial fluid were assessed.
Participants on treatment showed persistent beneficial effects of iPPS compared to
placebo. In the company’s view the biomarkers indicate cartilage sparing changes in
iPPS subjects compared to placebo.
Where to now
PAR will use the data to request a Type D meeting with the FDA in order to seek
guidance regarding the adequacy of its proposed endpoints in the upcoming phase 3
trials to support a future label claim for a disease modifying osteoarthritis drug
(DMOAD). If successful iPPS would be the first ever drug to attain this status. If the
label claim ultimately includes DMOAD, this may have significant implications for
revenues and valuation. Enrolment of the phase 3 program is continuing as planned.
Investment View: Buy (Speculative), Valuation $2.20
We retain our Buy (Speculative) rating and valuation of $2.20. The next major catalyst
will include the 12-month data from PARA_OA_008 later this year.
- Forums
- ASX - By Stock
- PAR
- Ann: iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study
Ann: iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study, page-134
-
- There are more pages in this discussion • 253 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
|
|||||
Last
23.5¢ |
Change
0.005(2.17%) |
Mkt cap ! $82.20M |
Open | High | Low | Value | Volume |
23.5¢ | 24.0¢ | 22.5¢ | $186.1K | 801.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 33599 | 23.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
23.5¢ | 65498 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 28599 | 0.230 |
6 | 177453 | 0.225 |
15 | 211076 | 0.220 |
6 | 98958 | 0.215 |
9 | 260864 | 0.210 |
Price($) | Vol. | No. |
---|---|---|
0.235 | 65498 | 1 |
0.240 | 7432 | 3 |
0.245 | 48923 | 2 |
0.250 | 18443 | 2 |
0.260 | 58362 | 1 |
Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online